Immunicum announces fully underwritten rights issue of about SEK 111 million to extend phase II-trial with new clinics in the US and to initiate clinical trials in melanoma in the US and in Sweden.
Read the press release here: Press release 160425 – Rights issue
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805